Current Atherosclerosis Reports

Article	Citations
Revascularization Options for Left Main Disease: What Clinicians Need to Know	88
Are Clinicians Aggressive Enough in Treating Diabetes-Related Hyperlipidemia in Youth?	84
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American Heart Association Scientific Sessions	81
Whether and Why Do We Need a Vaccine Against Atherosclerosis? Can We Expect It Anytime Soon?	78
Polysocial Risk Scores: Implications for Cardiovascular Disease Risk Assessment and Management	71
A Narrative Review of the Association Between Depression and Heart Disease Among Women: Prevalence, Mechanisms of Action, and Treatment	63
The Greatly Under-Represented Role of Smooth Muscle Cells in Atherosclerosis	59
The Expanding Scope of GLP-1 Receptor Agonists: Six Uses Beyond Diabetes	57
Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management	56
Heart Transplant, Kawasaki Disease, and Bone Marrow Transplant: Are There Consequences?	56
Ambient Air Pollution and Atherosclerosis: Recent Updates	54
Watermelon and l-Citrulline in Cardio-Metabolic Health: Review of the Evidence 2000–2020	52
PCSK9 Inhibition and Risk of Diabetes: Should We Worry?	50
The Effects of FABP4 on Cardiovascular Disease in the Aging Population	50
Polypharmacy and Cardiovascular Diseases: Consideration for Older Adults and Women	47
Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond	43
DOACs and Atherosclerotic Cardiovascular Disease Management: Can We Find the Right Balance Between Efficacy and Harm	43
Genetic Testing for Familial Hypercholesterolemia in Clinical Practice	42
From ‘Omics to Multi-omics Technologies: the Discovery of Novel Causal Mediators	41
Programmable Genome-Editing Technologies as Single-Course Therapeutics for Atherosclerotic Cardiovascular Disease	40
The Emerging Specialty of Cardio-Rheumatology	39
Inflammation in the Peri-ACS Period: Ready for Prime Time?	38
Nutrition Interventions for Youth with Dyslipidemia: Who, What, When, and Where?	36
Correction to: Beta‑blockers for Atherosclerosis Prevention: a Missed Opportunity?	36
The Role of Non-Statin Lipid Lowering Therapies to Reduce ASCVD Events in Primary Prevention	34

Recent Advances and Perspectives of Metabolomics-Based Investigations in Coronary Heart Disease	33
GLP-1 Receptor Agonists and Cardiovascular Disease: What Do Clinicians Need to Know?	33
The Intersection Between COVID-19, Cardiovascular Disease, and Diet: a Review	33
Percutaneous Coronary Interventions in Women	32
Myeloid Cells in Abdominal Aortic Aneurysm	31
Lipid Lowering Therapy Utilization and Lipid Goal Attainment in Women	31
RNA Silencing in the Management of Dyslipidemias	31
Implications of the Landmark ISCHEMIA Trial on the Initial Management of High-Risk Patients with Stable Ischemic Heart Disease	30
The Role of Sleep in Cardiovascular Disease	30
Lipoprotein(a): from Causality to Treatment	30
Implementing Reporting Standards for Polygenic Risk Scores for Atherosclerotic Cardiovascular Disease	29
Role of RNA-binding Proteins in Regulating Cell Adhesion and Progression of the Atherosclerotic Plaque and Plaque Erosion	29
Novel Therapies for Lipoprotein(a): Update in Cardiovascular Risk Estimation and Treatment	29
Low LDL-C: Is It all Good News?	29
Update on Plant-Based Diets and Cardiometabolic Risk	26
Effects of Omega-3 Fatty Acids on Flow-mediated Dilatation and Carotid Intima Media Thickness: A Meta-analysis	26
The Role of Bacterial Extracellular Membrane Nanovesicles in Atherosclerosis: Unraveling a Potential Trigger	25
Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) Equations: What Clinicians Need to Know?	25
Coronary Microvascular Dysfunction: What Clinicians and Investigators Should Know	25
In-Hospital Use of PCSK9 Inhibitors in the Post ACS Patient: What Does the Evidence Show?	24
Childhood Hypertriglyceridemia: Is It Time for a New Approach?	24
Importance of Nutrition Security to CVD Prevention Efforts in the USA	23
Stress, Vascular Smooth Muscle Cell Phenotype and Atherosclerosis: Novel Insight into Smooth Muscle Cell Phenotypic Transition in Atherosclerosis	23
Correction to: High-Density Lipoproteins and Serum Amyloid A (SAA)	22
Transgender Cardiovascular Health: Practical Management for the Clinician	22
Recent Advances in Stent Technology: Do They Reduce Cardiovascular Events?	21
Is Family History for the Management of Cardiovascular Health in Youth Still Relevant in Clinical Practice?	21
Dairy Foods: Is Its Cardiovascular Risk Profile Changing?	21
Eliminating Health Disparities in Atrial Fibrillation, Heart Failure, and Dyslipidemia: A Path Toward Achieving Pharmacoequity	20
Evidence Gaps in Assessments of the Healthiness of Online Supermarkets Highlight the Need for New Monitoring Tools: a Systematic Review	20
Noninvasive Atherosclerotic Phenotyping: The Next Frontier into Understanding the Pathobiology of Coronary Artery Disease	20
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American College of Cardiology Conference	20
Membrane Cholesterol Interactions with Proteins in Hypercholesterolemia-Induced Endothelial Dysfunction	19
SR-B1’s Next Top Model: Structural Perspectives on the Functions of the HDL Receptor	19
Is There a Role for Imaging Youth at Risk of Atherosclerosis?	19
Do Triglyceride-Rich Lipoproteins Equal Low-Density Lipoproteins in Risk of ASCVD?	19
Major Concepts in Treatment with Bempedoic Acid and Inclisiran that Clinicians Need To Know	19
Brief Review: Racial and Ethnic Disparities in Cardiovascular Care with a Focus on Congenital Heart Disease and Precision Medicine	18
Gene Regulatory Networks in Coronary Artery Disease	18
Clinical Management of Dyslipidemia in Infants and Toddlers	18
Cardiovascular Health and Disease in the Pakistani American Population	17
Pharmacotherapy for Coronary Artery Disease and Acute Coronary Syndrome in the Aging Population	17
Wall Shear Stress Alteration: a Local Risk Factor of Atherosclerosis	17
Natural Sirtuin1 Activators and Atherosclerosis: an Overview	16
Statin Use in Special Populations for the Prevention of Cardiovascular Disease in Adults	16
High Density Lipoprotein Particle Composition, Functionality, Deficiency, and Atherosclerotic Cardiovascular Disease Risk: A Review	16
Long-Term Cardiovascular Effects of COVID-19: Emerging Data Relevant to the Cardiovascular Clinician	16
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2025 American College of Cardiology Conference	16
Biology, Bias, or Both? The Contribution of Sex and Gender to the Disparity in Cardiovascular Outcomes Between Women and Men	16
Inclisiran, Reasons for a Novel Agent in a Crowded Therapeutic Field	15

What Causes Premature Coronary Artery Disease?	15
Targeting the Gut Microbiome to Treat Cardiometabolic Disease	15
Bempedoic Acid: for Whom and When	15
Anti-Inflammatory Lipid Mediators from Polyunsaturated Fatty Acids: Insights into their Role in Atherosclerosis Microenvironments	14
Management of Hypercholesterolemia in Pregnant Women with Atherosclerotic Cardiovascular Disease	14
Utility of FFRCT in Patients with Chest Pain	14
A Review of Statin Intolerance: a Focus on Statin-Attributed Muscle Symptoms	14
Managing Dyslipidemia in Chronic Kidney Disease: Implications for Cardiovascular and Renal Risk	14
Managing of Dyslipidaemia Characterized by Accumulation of Triglyceride-Rich Lipoproteins	14
Combined Dyslipidemia in Children and Adolescents: a Proposed New Management Approach	14
The Role of Lysyl Oxidase in the Pathological Stage of Atherosclerosis: Structural Stabilizer or Disease Driver?	13
Non-obstructive Plaque and Treatment of INOCA: More to Be Learned	13
Fixed Combination for the Treatment of Dyslipidaemia	13
Circular RNA role in Atherosclerosis Development and Progression	13
Extra-coronary Calcification and Cardiovascular Events: What Do We Know and Where Are We Heading?	13
Controversies in the Use of Omega-3 Fatty Acids to Prevent Atherosclerosis	13
Apheresis: What Should a Clinician Know?	12
Recent Updates in Hypertriglyceridemia Management for Cardiovascular Disease Prevention	11
Glycated Hemoglobin as an Integrator of Cardiovascular Risk in Individuals Without Diabetes: Lessons from Recent Epidemiologic Studies	11
Obicetrapib—the Rebirth of CETP Inhibitors?	11
Cardiovascular Disease Burden among African Migrants	11
Pregnancy Complications and Long-Term Atherosclerotic Cardiovascular Disease Risk	11
Unraveling the miRNA Puzzle in Atherosclerosis: Revolutionizing Diagnosis, Prognosis, and Therapeutic Approaches	11
Psoriasis and Cardiovascular Disease: Novel Mechanisms and Evolving Therapeutics	11
Lipids: a Potential Molecular Pathway Towards Diastolic Dysfunction in Youth-Onset Type 2 Diabetes	11
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2022 American Heart Association Scientific Sessions	11
The Effect of GLP-1 Receptor Agonists on Postprandial Lipaemia	11
Diet, Food Insecurity, and CVD Risk in Sexual and Gender Minority Adults	11
LDL-C: The Only Causal Risk Factor for ASCVD. Why Is It Still Overlooked and Underestimated?	11
Managing Ischemic Heart Disease in Women: Role of a Women’s Heart Center	11
European Lipid Guidelines and Cardiovascular Risk Estimation: Current Status and Future Challenges	11
Imaging Approaches to the Diagnosis of Vascular Diseases	11
Statins and Inflammation	11
Recent Advances in Coronary Computed Tomography Angiogram: The Ultimate Tool for Coronary Artery Disease	10
Can Digital Health Solutions Fill in the Gap for Effective Guideline Implementation in Cardiovascular Disease Prevention: Hope or Hype?	10
CETP Inhibitors: Should We Continue to Pursue This Pathway?	10
Inhibition of Angiopoietin-Like Protein 3 or 3/8 Complex and ApoC-III in Severe Hypertriglyceridemia	10
The TICE Pathway: Mechanisms and Potential Clinical Applications	10
Psychological Health and Ischemic Heart Disease in Women: A Review of Current Evidence and Clinical Considerations across the Healthspan	10
The Atherosclerotic Plaque Microenvironment as a Therapeutic Target	10
HDL as a Treatment Target: Should We Abandon This Idea?	10
Coronary and Extra-coronary Subclinical Atherosclerosis to Guide Lipid-Lowering Therapy	10
Targeting Inflammatory Pathways in Atherosclerosis: Exploring New Opportunities for Treatment	10
Advances, Challenges, and Progress in Cardiac Rehabilitation in Chronic CVD Management	9
An Update on Nutrition Guidance for Cardiovascular Health	9
Familial Hypercholesterolemia and Lipoprotein(a): Two Partners in Crime?	9
LDL Transcytosis by the Arterial Endothelium—Atherosclerosis by a Thousand Cuts?	9
Should Familial Hypercholesterolaemia Be Included in the UK Newborn Whole Genome Sequencing Programme?	9
Statin Use and Hyperglycemia: Do Statins Cause Diabetes?	9
Dietary Influences on Atherosclerotic Cardiovascular Disease Risk	9
Cholesterol Lowering in Older Adults: Should We Wait for Further Evidence?	9
Do Statins Affect Cognitive Health? A Narrative Review and Critical Analysis of the Evidence	9
How to Handle Elevated Triglycerides: Life after PROMINENT	9
Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors	9
Artificial Intelligence-Enabled Point-of-Care Echocardiography: Bringing Precision Imaging to the Bedside	9
Gene Editing for the Treatment of Hypercholesterolemia	9
Update on Sitosterolemia and Atherosclerosis	8
Achieving More Optimal Lipid Control with Non-Statin Lipid Lowering Therapy	8
Body Fat Depletion: the Yin Paradigm for Treating Type 2 Diabetes	8
Heart Failure Treatment in 2023: Is There a Place for Lipid Lowering Therapy?	8
Mechanisms Behind NAFLD: a System Genetics Perspective	8
Myocardial Bridge and Atherosclerosis, an Intimal Relationship	8
Can We Mitigate Coronary Heart Disease Risk in Patients with Cancer?	8
Nutraceuticals in the Management of Dyslipidemia: Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels?	8
JAM-A: Adhesion Receptor and Signaling Regulator in Atherosclerosis	8
Family Meals and Cardiometabolic Risk Factors in Young Children	8
Correction to: Recent Advances in Stent Technology: Do They Reduce Cardiovascular Events?	7
Correction to: Built Environment and Cardiovascular Diseases – Insights from a Global Review	7
Transitioning Adolescents and Young Adults with Lipid Disorders to Adult Health Care	7
Familial Combined Hyperlipidemia: Myth or Reality?	7
ADAMTS7: a Novel Therapeutic Target in Atherosclerosis	7
Lipoprotein Apheresis: Current Recommendations for Treating Familial Hypercholesterolemia and Elevated Lipoprotein(a)	7
Eggs and Cardiovascular Disease Risk: An Update of Recent Evidence	7
The Management of Hypercholesterolemia in Patients with Neuromuscular Disorder	7
Transitioning to GLP-1 RAs and SGLT2 Inhibitors as the First Choice for Managing Cardiometabolic Risk in Type 2 Diabetes	7
Correction to: Whether and Why Do We Need a Vaccine Against Atherosclerosis? Can We Expect It Anytime Soon?	7
Biomarkers Differentiating Plaque Erosion from Stable Plaque	7
The Role of Coronary Artery Calcium Testing for Value-Based Clinical Trials in Primary Prevention	7
Inclisiran: How Widely and When Should We Use It?	7
Effects of the COVID-19 Pandemic on Pediatric and Adolescent ASCVD Risk Factors	7

More than Just a Monolayer: the Multifaceted Role of Endothelial Cells in the Pathophysiology of Atherosclerosis	7
Health Literacy is Essential to ASCVD Prevention in Youth	7
“Anti-inflammatory Therapies in Atherosclerosis – Where are we going?”	7
Sport as Medicine for Dyslipidemia (and Other Risk Factors)	7
The Role of Non-statin Lipid-Lowering Medications in Youth with Hypercholesterolemia	7
Incidental Finding of Coronary and Non-Coronary Artery Calcium: What Do Clinicians Need To Know?	7
Double-Trouble: Atherosclerotic Risk Factors and Congenital Heart Disease	7
Built Environment and Cardiovascular Diseases – Insights from a Global Review	6
Impact of Sex Differences on Lipids and Statin Utilization	6
Invasive Coronary Assessment in Myocardial Ischemia with No Obstructive Coronary Arteries	6
Insight into the Mechanistic role of Colchicine in Atherosclerosis	6
Alcohol Consumption and Cardiovascular Disease Risk: Placing New Data in Context	6
Mechanosensing and Mechanosignal Transduction in Atherosclerosis	6
Updates in Small Interfering RNA for the Treatment of Dyslipidemias	6
Medical and Surgical Obesity Treatments and Atherosclerosis: Mechanisms beyond Typical Risk Factors	6
Statin Intolerance: an Overview of US and International Guidance	6
The Role of Cardiac PET in Diagnosis and Prognosis of Ischemic Heart Disease: Optimal Modality Across Different Patient Populations	6
Rap1 in the Context of PCSK9, Atherosclerosis, and Diabetes	6
Lipid Phenotypes and DNA Methylation: a Review of the Literature	6
The Role of Genetics in Advancing Cardiometabolic Drug Development	5
Novel Therapeutics for Familial Chylomicronemia Syndrome	5
Sex-based Differences in Complications Following Percutaneous Coronary Interventions	5
SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently?	5
Telomere Length: Implications for Atherogenesis	5
Predictive Modeling and Structure Analysis of Genetic Variants in Familial Hypercholesterolemia: Implications for Diagnosis and Protein Interaction Studies	5
Impact of Selective Peroxisome Proliferator-Activated Receptor (PPAR)-α Modulators and Fibrates on Microvascular Disease: Is There Still Room?	5
The Pandemic of Coronary Heart Disease in the Middle East and North Africa: What Clinicians Need to Know	5
Medical Nutrition Therapy Provided by Dietitians is Effective and Saves Healthcare Costs in the Management of Adults with Dyslipidemia	5
Updates in Drug Treatment of Severe Hypertriglyceridemia	5
Saturated Fat and Cardiovascular Health: Phenotype and Dietary Factors Influencing Interindividual Responsiveness	5
Prevention of Atherosclerotic Cardiovascular Disease in Children with Familial Hypercholesterolemia	5
Protective Effects of Different Classes, Intensity, Cumulative Dose-Dependent of Statins Against Primary Ischemic Stroke in Patients with Type 2 Diabetes Mellitus	5
ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future	5
Lp(a): A Rapidly Evolving Therapeutic Landscape	5
PCSK9 and Coronary Artery Plaque—New Opportunity or Red Herring?	5
Evolution of Coronary Calcium Screening for Assessment of Atherosclerotic Cardiovascular Disease Risk and Role in Preventive Cardiology	5
Medication Induced Dyslipidemia in Children	5